Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1800 results
November 2015
-
Giraffes have high blood pressure. Why don’t they drop dead?
A certain leggy resident of the African grasslands is arousing a lot of interest among evolutionary biologists. They believe that study of giraffes' unique features could lead the way to advances in human health.
-
Media ReleaseNovartis nominating Elizabeth Doherty and Ton Buechner to the Board of DirectorsNominees for election by shareholders at Annual General Meeting (AGM) in February 2016 Basel, November 4, 2015 - The Novartis Board of Directors announced today, that it is nominating Ms.…
October 2015
-
Media ReleaseNovartis Foundation and partners launch new hypertension program in GhanaCommunity-based Hypertension Improvement Project (ComHIP) is an innovative healthcare model designed to improve hypertension management and control Screening and treatment is shifted to the…
-
Stepping toward regenerative medicine for diabetes
Discovery points toward treatment options beyond insulin injections
-
Compounds spur insulin-producing cells to replicate in the lab
-
Media ReleaseNovartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidanceSolid growth (cc[1]) in Q3 sales, core operating income, core EPS for continuing operations[2] Net sales were USD 12.3 billion (-6%, +6% cc) Operating income was USD 2.2 billion (-18%, +2% cc) Core…
-
Media ReleaseNovartis a réalisé, au troisième trimestre, une forte hausse de sa marge core (tcc) et continué de renforcer son pipeline, confirmant ainsi ses prévisions pour l'exerciceCroissance solide (tcc[1]), au T3, des ventes, du résultat opérationnel core et du BPA core des activités poursuivies[2] Chiffre d'affaires net d'USD 12,3 milliards (-6%, +6% tcc) Résultat…
-
Media ReleaseNovartis steigert die Kerngewinnmarge (kWk) im dritten Quartal kräftig, stärkt erneut die Pipeline und ist auf Kurs für die JahresprognoseSolides Wachstum (kWk[1]) im dritten Quartal beim Umsatz, operativen Kernergebnis und Kerngewinn pro Aktie der fortzuführenden Geschäftsbereiche[2]: Der Nettoumsatz beläuft sich auf USD 12,3…
-
Media ReleaseNovartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx(TM) to treat ankylosing spondylitis and psoriatic arthritisCosentyx (secukinumab) is recommended for approval in Europe for the treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients Cosentyx demonstrated rapid onset of…
-
Media ReleaseNovartis broadens immuno-oncology pipeline with acquisition of Admune Therapeutics and licensing agreements with XOMA and PalobiofarmaWith four programs currently in clinical trials and five more expected to enter the clinic by the end of 2016, Novartis has rapidly built a robust portfolio of programs focused on stimulating the…
-
Clinical trials make a move toward mice
By growing human tumors in mice, NIBR develops a unique system that seeks to mimic clinical trials of cancer drugs
-
Delivering access: first launch in Kenya
Chronic diseases kill 38 million people per year worldwide; almost three-quarters of those deaths occur in low- and middle-income countries. It’s time to act.
Pagination
- ‹ Previous page
- 1
- …
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- …
- 150
- › Next page